Karyopharm Therapeutics IncQ) expected to post a loss of $4.10 a share - Earnings Preview
Karyopharm Therapeutics IncQ) is anticipated to report a loss of $4.10 per share and a 13.7% decline in quarterly revenue to $36.935 million for the period ending June 30, 2025. The average analyst rating remains "buy" with a median 12-month price target of $15.00, significantly above its last closing price of $3.81. Recent quarterly performances show a mix of beats and misses against estimates, with the latest earnings estimate unchanged over the past three months.
- Karyopharm Therapeutics Inc (KPTI.OQ) (KPTI.O) is expected to
show a fall in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025
- The Newton Massachusetts-based company is expected to report a 13.7% decrease in revenue to $36.935 million from $42.79 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
- LSEG’s mean analyst estimate for Karyopharm Therapeutics Inc is for a loss of $4.10 per share.
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 5 “strong buy” or “buy,” 2 “hold” and no “sell” or “strong sell.”
- The mean earnings estimate of analysts was unchanged in the last three months.
- Wall Street’s median 12-month price target for Karyopharm Therapeutics Inc is $15.00, about 74.6% above its last closing price of $3.81 Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2025 -4.21 -4.18 -2.77 Beat 33.7
Dec. 31 2025 -4.32 -3.92 -3.60 Beat 8.2
Sep. 30 2024 -3.76 -3.94 -3.90 Beat 1.1
Jun. 30 2024 -4.31 -4.48 2.25 Beat 150.2
Mar. -4.93 -5.01 -4.80 Beat 4.2
31 2024
Dec. 31 2023 -4.68 -4.65 -5.40 Missed -16.2
Sep. 30 2023 -4.26 -4.20 -4.50 Missed -7.1
Jun. 30 2023 -5.26 -5.13 -4.35 Beat 15.3
This summary was machine generated August 1 at 13:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
